12:00 AM
Sep 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Triptorelin pamoate: Phase III started

Debiopharm began an open-label, international Phase III trial to evaluate 2 intramuscular injections of a 6-month formulation of 22.5 mg triptorelin pamoate in 44 children with CPP. The product's active ingredient, triptorelin, is marketed in more than 80 countries for various indications, including advanced prostate cancer and CPP.

Watson has rights to triptorelin...

Read the full 246 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >